Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Digital stories could ease tough transplant decisions for blood cancer patients

NCT ID NCT07263074

Knowledge-focused Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests a new approach called CHORDS, which uses short digital stories from past patients and simple values exercises to help people with myeloid cancers think through their decision about a stem cell transplant. About 120 patients will be randomly assigned to receive CHORDS or usual care. The main goal is to see if the program is practical and whether it helps patients feel more involved in their own care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digital story intervention (CHORDS)
What this could lead to
If it works, this could give doctors and patients a new tool to make better, more personal decisions about whether to proceed with a stem cell transplant.
What could go wrong
This is a small, early feasibility study, not a large trial. It may not show clear benefits, and the digital stories may not help everyone equally.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients Inclusion criteria: 1. Age \>21 years old 2. Diagnosis of myeloid cancer (e.g. AML, MDS, myelofibrosis, CML, or MDS/MPN) 3. Being considered for alloHCT 4. Able to provide informed consent 5. Able to speak English. The reason for this is because the digital stories have been created in the English language and their multimedia form cannot easily be translated. Exclusion criteria 1) Patients with psychiatric or cognitive conditions which the hematologist believes prohibits informed consent or compliance with study procedures Caregivers Inclusion criteria: 1. Age \>18 years old 2. Selected by the patient when asked if there is a "family member, partner, friend or caregiver with whom you discuss or who can be helpful in health-related matters." 3. Caregiver may be paid/professional or informal caregiver 4. Able to provide informed consent 5. Able to speak English Exclusion Criteria: 1\) None Hematologists Inclusion criteria: 1\) Hematologists of the patients who agree to enroll on the study who are part of WCI. Exclusion criteria 1\) None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myeloid malignancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myeloid malignancy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Rochester

    RECRUITING

    Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.